

Urea Cycle Disorders Market Set for Strong Growth by 2034, Predicts DelveInsight

DelveInsight's report on Urea Cycle Disorders provides a comprehensive analysis of the epidemiology and market trends across the 7MM.

LAS VEGAS , NV, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- DelveInsight's "Urea Cycle Disorders Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the Urea Cycle Disorders market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [Urea Cycle Disorders Market Forecast](#)

Some of the key facts of the Urea Cycle Disorders Market Report:

- The Urea Cycle Disorders market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- Among all urea cycle disorders (UCDs), ornithine transcarbamylase deficiency (OTCD) is the most common, transmitted as an X-linked trait.
- UCDs have an estimated incidence of 1 in every 8,000–44,000 births, with OTCD being the most prevalent disorder, followed by citrullinemia and argininosuccinic aciduria.
- A study by Hernández et al. (2014) found that OTCD accounted for 64.4% of UCD cases in Spain, followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%).
- The estimated incidence of UCDs in the U.S. is 1 in 35,000 live births, equating to approximately 113 new patients per year.
- In April 2024, iECURE received FDA clearance for its Investigational New Drug (IND) application for ECUR-506 for OTCD.
- In December 2023, the European Commission granted marketing authorization for LOARGYS (pegzilarginase) to treat ARG1-D in patients aged 2 years and older, and the company plans to re-submit a Biologics License Application (BLA) to the FDA for the treatment of arginase 1 deficiency.
- In January 2023, the FDA approved Olpruva (sodium phenylbutyrate) for certain patients with UCDs to manage ammonia buildup, which can lead to brain damage and cognitive impairments.
- Emerging drugs for UCDs include DTX301, LUNAR-OTC (ARCT-810), ECUR-506, and others.

- Key companies in the UCD space include Acer Therapeutics, Dimension Therapeutics, Callitas Therapeutics, Poseida Therapeutics, Promethera Biosciences, Arcturus Therapeutics, Kaleido Biosciences, Akaza Biopharma, Evox Therapeutics, Dipharma SA, Sana Biotechnology, Aeglea BioTherapeutics, ERYTECH, and others.
- The Spinocerebellar Ataxia market is expected to experience substantial growth, driven by the rising demand for effective therapies, advances in genetic research, and ongoing clinical trials focused on improving patient outcomes for this rare neurodegenerative disease.

Urea Cycle Disorders Overview

The Urea Cycle Disorders Treatment Market is a vital part of the pharmaceutical industry focused on addressing rare genetic disorders known as urea cycle disorders (UCDs). These conditions hinder the body's ability to process nitrogen waste properly, resulting in dangerous ammonia buildup in the bloodstream. The market includes various innovative therapies and treatments aimed at managing UCD symptoms and enhancing patients' quality of life. DelveInsight's Urea Cycle Disorders market report provides an in-depth overview of UCDs, covering aspects such as disease definition, symptoms, causes, pathophysiology, diagnosis, and available treatments.

Get a Free sample for the Urea Cycle Disorders Market Report:

https://www.delveinsight.com/report-store/urea-cycle-disorders-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr

Urea Cycle Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Urea Cycle Disorders Epidemiology Segmentation:

The Urea Cycle Disorders market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Incident Cases of Urea Cycle Disorders in the US
- Onset-specific Cases of Urea Cycle Disorders in the US
- Type-specific Cases of Urea Cycle Disorders in the US
- Diagnosed and Treatable Cases of Urea Cycle Disorders in the US

Download the report to understand which factors are driving Urea Cycle Disorders epidemiology trends @ [Urea Cycle Disorders Epidemiology Forecast](#)

Urea Cycle Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urea Cycle Disorders market or expected to be launched during the study period. The analysis covers Urea Cycle Disorders market uptake by drugs, patient uptake by therapies, and

sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Urea Cycle Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Urea Cycle Disorders Therapies and Key Companies

- DTX301: Ultragenyx Pharmaceutical
- LUNAR-OTC (ARCT-810): Arcturus Therapeutics
- ECUR-506: iECURE

Urea Cycle Disorders Market Strengths

- Increasing awareness about UCDs among healthcare professionals and advancements in diagnostic techniques are leading to earlier detection and better patient outcomes.
- The development of novel therapies, such as sodium phenylbutyrate and pegzilarginase, along with recent FDA approvals, is driving market growth and improving treatment options for UCD patients.

Urea Cycle Disorders Market Opportunities

- There is significant potential for the development of new therapies targeting specific UCD subtypes, addressing unmet medical needs for more effective and personalized treatments.
- The growing healthcare infrastructure in emerging markets presents opportunities for expanding access to UCD treatments and increasing patient reach globally.

Scope of the Urea Cycle Disorders Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Urea Cycle Disorders Companies: Acer Therapeutics, Dimension Therapeutics, Callitas Therapeutics, Poseida Therapeutics, Promethera Biosciences, Arcturus Therapeutics, Kaleido Biosciences, Akaza Biopharma, Evox Therapeutics, Dipharma SA, Sana Biotechnology, Aeglea BioTherapeutics, ERYTECH, and others.
- Key Urea Cycle Disorders Therapies: DTX301, LUNAR-OTC (ARCT-810), ECUR-506, and others.
- Urea Cycle Disorders Therapeutic Assessment: Urea Cycle Disorders current marketed and Urea Cycle Disorders emerging therapies
- Urea Cycle Disorders Market Dynamics: Urea Cycle Disorders market drivers and Urea Cycle Disorders market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Urea Cycle Disorders Unmet Needs, KOL's views, Analyst's views, Urea Cycle Disorders Market Access and Reimbursement

To learn more about Urea Cycle Disorders companies working in the treatment market, visit @ [Urea Cycle Disorders Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Urea Cycle Disorders Market Report Introduction
2. Executive Summary for Urea Cycle Disorders
3. SWOT analysis of Urea Cycle Disorders
4. Urea Cycle Disorders Patient Share (%) Overview at a Glance
5. Urea Cycle Disorders Market Overview at a Glance
6. Urea Cycle Disorders Disease Background and Overview
7. Urea Cycle Disorders Epidemiology and Patient Population
8. Country-Specific Patient Population of Urea Cycle Disorders
9. Urea Cycle Disorders Current Treatment and Medical Practices
10. Urea Cycle Disorders Unmet Needs
11. Urea Cycle Disorders Emerging Therapies
12. Urea Cycle Disorders Market Outlook
13. Country-Wise Urea Cycle Disorders Market Analysis (2020–2034)
14. Urea Cycle Disorders Market Access and Reimbursement of Therapies
15. Urea Cycle Disorders Market Drivers
16. Urea Cycle Disorders Market Barriers
17. Urea Cycle Disorders Appendix
18. Urea Cycle Disorders Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/779297368>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.